scholarly journals MT4 MIXED TREATMENT COMPARISON (MTC) OF ANTIFUNGAL DRUGS FOR PROPHYLAXIS TREATMENT AGAINST INVASIVE FUNGAL INFECTIONS (IFIS) IN PATIENTS RECEIVING CHEMOTHERAPY FOR HEMATOLOGICAL MALIGNANCIES OR ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION

2010 ◽  
Vol 13 (7) ◽  
pp. A245
Author(s):  
P Pechlivanoglou ◽  
HH Le ◽  
R De Vries ◽  
MJ Postma
Keyword(s):  
Stem Cells ◽  
Hematological Malignancies ◽  
Fungal Infections ◽  
Antifungal Drugs ◽  
Mixed Treatment Comparison ◽  
Hematopoietic Stem ◽  
Treatment Comparison ◽  
Mixed Treatment ◽  
Stem Cells Transplantation ◽  
Hematopoietic Stem Cells Transplantation

scholarly journals ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS

2016 ◽  
Vol 8 ◽  
pp. e2016040 ◽  
Author(s):  
Lourdes Vazquez
Keyword(s):  
Gold Standard ◽  
Concomitant Medication ◽  
Hematological Malignancies ◽  
Fungal Infections ◽  
Antifungal Prophylaxis ◽  
Antifungal Drugs ◽  
Risk Of Infection ◽  
Scientific Societies ◽  
Hematopoietic Stem ◽  
Poor Efficacy

Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations with a high risk of infection, such as acute leukemia, myelodysplastic syndromes, and autologous or allogeneic hematopoietic stem cell transplantation. Over the years, various scientific societies have established a series of recommendations for antifungal prophylaxis based on prospective studies performed with different drugs. However, the prescription of each agent must be personalized, adapting its administration to the characteristics of individual patients and taking into account possible interactions with concomitant medication.

Sign in / Sign up

Export Citation Format

Share Document